DRUG INTERACTIONS IN EMERGENCY MEDICINE: AN OVERVIEW SCOTT LINSCOTT, MD UNIVERSITY OF UTAH SCHOOL OF MEDICINE DRUG INTERACTIONS • PREVALANCE • MECHANISMS • MOST COMMON • THOSE WITH HIGHEST MORBIDITY / MORTALITY • MOST ARE UNPREDICTABLE PREVALANCE • HERR, LINSCOTT, ET AL - 1992 • 340 CONSECUTIVE PATIENTS IN THE ED: FOUND 135 POTENTIAL DRUG INTERACTIONS • 20 CLINICALLY RELEVANT DI IN 15 PTS • INCIDENCE HIGHER AMONG DRUGS PTS ON CURRENTLY THAN MEDS PRESCRIBED IN THE ED (9.7% VS 3.1%) PREVALANCE • 10 PTS: PRESENTING SYMPTOMS WERE DUE TO DRUG-DRUG INTERACTIONS • ONE FATALITY: PATIENT ON COUMADIN, PUT ON CIPRO – INR WAS 15 AND THE PATIENT HAD A FATAL GI HEMORRHAGE • ONLY PREDICTOR OF CLINICAL RELEVANCE WAS AGE >60 MECHANISMS • • • • • • P-450 ENZYME INDUCTION P-450 ENZYME INHIBITION GI ABSORPTION GI DRUG BINDING DRUG EXCRETION PROTEIN BINDING COMPETITION P-450 ENZYME INDUCTION • • CAUSES DECREASED EFFECT OF OBJECT DRUG: WARFARIN, TCA, DISOPYRAMIDE, QUINIDINE, THEOPHYLLINE DRUGS WHICH MAY INDUCE P450 ENZYMES: • PROTEASE INHIBITORS AND NNRTIs (RITONAVIR) • BARBITURATES, PRIMIDONE (MYSOLINE) • CARBAMAZEPINE (TEGRETOL) • PHENYTOIN (DILANTIN) • RIFAMPIN • SMOKING (THEOPHYLLINE) P-450 ENZYME INDUCTION • EFFECT TAKES SEVERAL DAYS ( >7 DAYS) TO BECOME CLINICALLY SIGNIFICANT • MAY NEED TO INCREASE DOSE OF OBJECT DRUG TO OBTAIN DESIRED EFFECT • IF STOP THE INDUCING DRUG, MAY DEVELOP SIGNIFICANT TOXICITY OF OBJECT DRUG • BEST TO DECREASE THE DOSE OF OBJECT DRUG BEFORE STOPPING INDUCING DRUG P-450 ENZYME INHIBITION • MOST DRUGS ARE METABOLIZED BY MIXED FUNCTION OXIDASES (CYTOCHROME P450 ISOENZYMES IA2, IIC9, IID6, & IIIA4) • DRUGS WHICH COMPETITIVELY INHIBIT THE P450 SYSTEM MAY DECREASE METABOLISM OF THE OBJECT DRUG AND LEAD TO TOXICITY • UNLIKE ENZYME INDUCTION, THIS EFFECT OCCURS VERY SOON (WITHIN 24 HRS) OF STARTING THE INHIBITING DRUG P-450 ENZYME INHIBITION • DEGREE OF INHIBITION IS USUALLY DEPENDENT UPON THE DOSE OF THE INHIBITING DRUG (CIMETIDINE < 400 mg DAILY IS UNLIKELY TO SIGNIFICANTLY INHIBIT THE P450 ENZYME SYSTEM AND CAUSE OBJECT DRUG TOXICITY) • USE PEPSID-AC RATHER THAN TAGAMET-HB • TOXICITY OF OBJECT DRUG DEPENDS ON ITS INITIAL LEVEL (IF HIGH INITIALLY, MORE LIKELY TO CAUSE TOXICITY, ie INITIALLY HIGH INR - CIPRO) P-450 ENZYME INHIBITION • MOST COMMON MECHANISM OF DRUG INTERACTIONS • MOST COMMON CAUSE OF MORTALITY AND SEVERE MORBIDITY AMONG DIs • ALL NEW DRUGS WHICH ARE METABOLIZED BY THE LIVER MUST BE TESTED WITH CIMETIDINE (OTC) INHIBIT THE P-450 ENZYME SYSTEM • • • • • • • • • • • • • CIMETIDINE AMIODARONE FLUOXETINE, PAROXETINE, FLUVOXAMINE VERAPAMIL OMEPRAZOLE PROTEASE INHIBITORS AND NNRTIs (RITONAVIR) QUINIDINE ERYTHROMYCIN, CLARITHROMYCIN INH TMP-SMZ CIPROFLOXACIN (ESP. COUMADIN) KETOCONAZOLE GRAPEFRUIT JUICE COMPETITION FOR RENAL TUBULAR EXCRETION • DIGOXIN – QUINIDINE • DIGOXIN – AMIODARONE • DIGOXIN – VERAPAMIL • NSAIDs - METHOTREXATE GI ABSORPTION • ALTERATIONS IN MOTILITY: ACETAMINOPHEN ABSORPTION IS INCREASED BY REGLAN & ERYTHROMYCIN AND DECREASED BY PROBANTHINE • ALTERATIONS IN pH: KETOCONAZOLE REQUIRES A LOW GASTRIC pH TO DISSOLVE ADEQUATELY FOR ABSORPTION. H2 BLOCKERS, PPIs, AND ANTACIDS DECREASE ITS BIOAVAILABILITY GI – DRUG BINDING • ANTACIDS + CIPRO (CHELATION) • ANTACIDS + TCN (CHELATION) • IRON + TCN (CHELATION) • CHOLESTYRAMINE + WARFARIN (RESIN BINDING) • MOST DRUGS + ACTIVATED CHARCOAL (ADVANTAGEOUS IN OVERDOSES) PROTEIN BINDING DISPLACEMENT • PREVIOUSLY FELT TO BE A COMMON AND IMPORTANT DRUG INTERACTION • ONLY CLINICALLY IMPORTANT IF OBJECT DRUG IS HIGHLY PROTEIN BOUND (WARFARIN) • WHEN OBJECT DRUG IS DISPLACED, MORE OF IT ENTERS THE TISSUES AND ITS METABOLISM INCREASES → DECREASED FREE DRUG • THEREFORE, THE EFFECT IS VERY TRANSIENT AND ONLY IMPORTANT IF INTIAL LEVEL OF OBJECT DRUG IS HIGH (EXCESS PROTHROMBIN TIME/INR) MISCELLANEOUS • TCA + EPINEPHRINE = HYPERADRENERGIC STATE (USE 0.05 - 0.1 mg SQ) • TCA + FLUOXETINE (PROZAC), PAROXETINE (PAXIL), FLUVOXAMINE (LUVOX) = TCA TOXICITY (DUE TO P450 INHIBITION) - NOT A PROBLEM WITH SERTRALINE (ZOLOFT) • AMINOGLYCOSIDE + ETHACRYNIC ACID = OTOTOXIC • ACEI + K+ SPARING DIURETICS / K+ / NSAIDs = HYPERKALEMIA SUMMARY • Most are uncommon and unpredictable • A few are associated with significant morbidity and mortality, esp. warfarin • Best book: Hansten and Horn: Managing Clinically Important Drug Interactions (2003) (www.drugfacts.com) • Computer programs (online and CD-ROM): • Drug-Reax (Micromedex: www.micromedex.com) • Drug Interaction Facts (www.drugfacts.com) • PDA based programs: • Lexi-Interact (www.lexi-comp.com) • iFacts and DrugIx (www.skyscape.com)